Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic.

Islam MR, Nishie M, Nagao J, Zendo T, Keller S, Nakayama J, Kohda D, Sahl HG, Sonomoto K.

J Am Chem Soc. 2012 Feb 29;134(8):3687-90. doi: 10.1021/ja300007h. Epub 2012 Feb 17.

PMID:
22329487
2.

Antimicrobial mechanism of lantibiotics.

Islam MR, Nagao J, Zendo T, Sonomoto K.

Biochem Soc Trans. 2012 Dec 1;40(6):1528-33. doi: 10.1042/BST20120190. Review.

PMID:
23176511
3.

LiaRS reporter assay: A simple tool to identify lipid II binding moieties in lantibiotic nukacin ISK-1.

Elsayed KM, Islam MR, Abdullah-Al-Mahin, Nagao JI, Zendo T, Sonomoto K.

J Biosci Bioeng. 2017 Mar;123(3):398-401. doi: 10.1016/j.jbiosc.2016.10.002. Epub 2016 Nov 14.

PMID:
27856233
4.

The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II.

Wiedemann I, Böttiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, Deegan L, Hill C, Ross P, Sahl HG.

Mol Microbiol. 2006 Jul;61(2):285-96. Epub 2006 Jun 12.

5.

Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning.

Islam MR, Shioya K, Nagao J, Nishie M, Jikuya H, Zendo T, Nakayama J, Sonomoto K.

Mol Microbiol. 2009 Jun;72(6):1438-47. doi: 10.1111/j.1365-2958.2009.06733.x. Epub 2009 May 8.

6.

Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors.

Müller A, Ulm H, Reder-Christ K, Sahl HG, Schneider T.

Microb Drug Resist. 2012 Jun;18(3):261-70. doi: 10.1089/mdr.2011.0242. Epub 2012 Mar 20.

PMID:
22432708
7.

Lipid II-based antimicrobial activity of the lantibiotic plantaricin C.

Wiedemann I, Böttiger T, Bonelli RR, Schneider T, Sahl HG, Martínez B.

Appl Environ Microbiol. 2006 Apr;72(4):2809-14.

8.

Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.

Böttiger T, Schneider T, Martínez B, Sahl HG, Wiedemann I.

Appl Environ Microbiol. 2009 Jul;75(13):4427-34. doi: 10.1128/AEM.00262-09. Epub 2009 May 8.

9.

An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.

Hasper HE, Kramer NE, Smith JL, Hillman JD, Zachariah C, Kuipers OP, de Kruijff B, Breukink E.

Science. 2006 Sep 15;313(5793):1636-7.

10.

Lysine-oriented charges trigger the membrane binding and activity of nukacin ISK-1.

Asaduzzaman SM, Nagao J, Aso Y, Nakayama J, Sonomoto K.

Appl Environ Microbiol. 2006 Sep;72(9):6012-7.

11.

Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity.

Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG.

J Biol Chem. 2001 Jan 19;276(3):1772-9. Epub 2000 Oct 18.

12.
13.

Mapping and identification of the region and secondary structure required for the maturation of the nukacin ISK-1 prepeptide.

Nagao J, Morinaga Y, Islam MR, Asaduzzaman SM, Aso Y, Nakayama J, Sonomoto K.

Peptides. 2009 Aug;30(8):1412-20. doi: 10.1016/j.peptides.2009.05.021. Epub 2009 May 27.

PMID:
19481127
14.

NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity.

Hsu ST, Breukink E, Bierbaum G, Sahl HG, de Kruijff B, Kaptein R, van Nuland NA, Bonvin AM.

J Biol Chem. 2003 Apr 11;278(15):13110-7. Epub 2003 Jan 31.

15.

Lantibiotic engineering: molecular characterization and exploitation of lantibiotic-synthesizing enzymes for peptide engineering.

Nagao J, Aso Y, Shioya K, Nakayama J, Sonomoto K.

J Mol Microbiol Biotechnol. 2007;13(4):235-42.

PMID:
17827974
16.

Nukacin ISK-1, a bacteriostatic lantibiotic.

Asaduzzaman SM, Nagao J, Iida H, Zendo T, Nakayama J, Sonomoto K.

Antimicrob Agents Chemother. 2009 Aug;53(8):3595-8. doi: 10.1128/AAC.01623-08. Epub 2009 Jun 8.

17.

Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics.

de Kruijff B, van Dam V, Breukink E.

Prostaglandins Leukot Essent Fatty Acids. 2008 Sep-Nov;79(3-5):117-21. doi: 10.1016/j.plefa.2008.09.020. Epub 2008 Nov 12. Review.

PMID:
19008088
18.

A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of the structural gene and identification of the structure.

Sashihara T, Kimura H, Higuchi T, Adachi A, Matsusaki H, Sonomoto K, Ishizaki A.

Biosci Biotechnol Biochem. 2000 Nov;64(11):2420-8.

19.

Expanding role of lipid II as a target for lantibiotics.

Martin NI, Breukink E.

Future Microbiol. 2007 Oct;2(5):513-25. Review.

PMID:
17927474
20.

Microtiter plate bioassay to monitor the interference of antibiotics with the lipid II cycle essential for peptidoglycan biosynthesis.

Burkard M, Stein T.

J Microbiol Methods. 2008 Sep;75(1):70-4. doi: 10.1016/j.mimet.2008.05.002. Epub 2008 May 13.

PMID:
18558445

Supplemental Content

Support Center